With BRCA2+ and on high-dose transdermal estrogen, I happened to see a reply by Richard Wassersug hidden in a thread a long time ago, about the possible danger of t2E causing accelerated prostate cancer growth for those with BRCA+ disease.
I recently contacted him and he told me that he feels that this still holds, but acknowledges that there have been no clinical trials published that specifically document that.
The topic of the pros and cons of transdermal E2 and ADT is briefly summarized in the new European edition of the ADT book that he is the lead author on. The book came out in July, was reviewed by a number of MDs in Europe who treat PCa, and is officially endorsed by the European Association of Urology. I can highly recommend the book.